

Special Issue

Jellyfish and Polyps: Cnidarians as Sustainable Resources for Biotechnological Applications and Bioprospecting - II

Message from the Guest Editors

Sea anemones, corals, and less familiar forms of benthic polypoid cnidarians limited swimming ability, and their wide biodiversity with about 13,400 living described species make cnidarians top candidates for the development of biochemical strategies for survival (feeding, defense) and reproduction, including symbiosis or other relationships with microbes and other organisms. Venomous compounds occurring in extracts of cnidarians are viewed with particular interest for both of the aims, as well as the mitigation of their adverse effects and their possible beneficial use for humans. Furthermore, in the pharmacopeia of traditional medicine of Eastern countries, jellyfish are regarded as a treatment for disorders and diseases and represent a valuable foodstuff with health benefits, suggesting the occurrence of bioactive compounds.


This Special Issue will collect novel research papers and original reviews focusing on bioprospecting marine cnidarians and on the exploitation of their biomasses and derived compounds for biotechnological and biomedical applications, as well as active ingredients for pharmaceutical, nutraceutical, cosmetic, and cosmeceutical uses.

Guest Editors

Dr. Antonella Leone
Dr. Gian Luigi Mariottini
Prof. Dr. Stefano Piraino

Deadline for manuscript submissions

closed (31 December 2021)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/30744

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))